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Parathyroid hormone-related protein (PTHrP) is pro-
duced by the pancreatic islet. It also has receptors on
islet cells, suggesting that it may serve a paracrine or
autocrine role within the islet. We have developed trans-
genic mice, which overexpress PTHrP in the islet
through the use of the rat insulin II promoter (RIP).
Glucose homeostasis in these mice is markedly abnor-
mal; RIP-PTHrP mice are hypoglycemic in the post-
prandial and fasting states and display inappropriate
hyperinsulinemia. At the end of a 24-hour fast, blood
glucose values are 49 mg/dl in RIP-PTHrP mice, as com-
pared to 77 mg/dl in normal littermates; insulin concen-
trations at this time are 6.3 and 3.9 ng/ml, respectively.
Islet perifusion studies failed to demonstrate abnormal-
ities in insulin secretion. In contrast, quantitative islet
histomorphometry demonstrates that the total islet
number and total islet mass are 2-fold higher in RIP-
PTHrP mice than in their normal littermates.
PTHrP very likely plays a normal physiologic role
within the pancreatic islet. This role is most likely para-
crine or autocrine. PTHrP appears to regulate insulin
secretion either directly or indirectly, through develop-
mental or growth effects on islet mass. PTHrP may have
a role as an agent that enhances islet mass and/or en-
hances insulin secretion.
Parathyroid hormone-related protein (PTHrP)1 was initially
discovered in 1987 through its causative role in the most com-
mon of the hypercalcemic paraneoplastic syndromes, humoral
hypercalcemia of malignancy (1–3). It is now widely appreci-
ated that PTHrP is the product of a gene, which is expressed
not only in a broad spectrum of human and animal cancers, but
in almost every normal human and rodent tissue in which its
expression has been sought (3, 4, 6). Oversecretion of PTHrP
into the systemic circulation by cancers (including carcinomas
of the pancreatic islet; Ref. 7–9) leads to hypercalcemia in a
classical endocrine fashion through binding of PTHrP to para-
thyroid hormone receptors in bone and kidney (1–6, 10). In
contrast, there is growing consensus that the normal physio-
logic roles of PTHrP are most often paracrine or autocrine
(1–6), or perhaps even “intracrine” as suggested by Kaiser,
Karaplis, and colleagues (11, 12). The study of the normal
physiologic roles of PTHrP is in its infancy. These roles have
been reviewed recently (3–6, 13) and appear to include: 1)
regulation of transepithelial calcium fluxes in the nephron, in
the breast, in the placenta, and in the distal oviduct or shell
gland of the hen; 2) regulation of uterine, vascular, gastroin-
testinal, and urinary bladder smooth muscle tone; 3) regulation
of growth and differentiation in a broad variety of cell types and
organs including the keratinocyte, the chondrocyte, the osteo-
blast, the cells of the proximal nephron, the breast, and many
others. Importantly in the current context, PTHrP is a key
developmental factor. This is apparent from the fact that in
each of the transgenic mouse models of PTHrP overexpression
or of disruption of the PTHrP gene or its receptor, dramatic
developmental abnormalities occur: targeted overexpression of
PTHrP in the breast leads to striking mammary ductular hy-
poplasia (14), and overexpression of PTHrP in the epidermal
keratinocyte leads to failure of hair follicle development (15).
Disruption of the PTHrP gene or its receptor leads to severe
and lethal skeletal developmental abnormalities (16, 17).
One of the tissues that produces PTHrP under normal cir-
cumstances is the pancreatic islet. Drucker, Goltzman, and
colleagues have shown that PTHrP can be identified in normal
rat and human pancreatic islets; that PTHrP colocalizes im-
munohistochemically with insulin, glucagon, somatostatin,
and pancreatic polypeptide in b, a, d, and PP cells within the
islet; and that mRNA encoding PTHrP is present in isolated rat
pancreatic islets (7). PTHrP is also produced by islet cell ade-
nomas and carcinomas (7–9). We have confirmed that PTHrP is
present immunohistochemically in the rat islet (18) and, as
shown below, the mouse islet. We have shown that cultured rat
insulinoma cells of the line m5F display cytosolic calcium re-
sponses to doses of PTHrP within the physiologic range, and
that these responses are mediated by receptors distinct from
the classical PTH receptor (18). The observations: (a) that
PTHrP is normally produced in the pancreatic b cell, (b) that
pancreatic b cells contain receptors for PTHrP, and (c) that
under all normal circumstances studied to date, PTHrP plays
local paracrine or autocrine roles, together suggested that
PTHrP could play a normal regulatory or developmental role
within the pancreatic islet.
In order to begin to define a possible normal physiologic role
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for PTHrP in the pancreatic islet, we have prepared two lines of
transgenic mice in which PTHrP has been targeted to, and
overexpressed in, the pancreatic islet using the rat insulin II
promoter (RIP). These RIP-PTHrP mice display a syndrome
that includes islet cell hyperplasia, hyperinsulinemia, and
hypoglycemia.
MATERIALS AND METHODS
Construction of Transgene and Generation of Transgenic Mice—The
RIP-PTHrP transgene was constructed by placing a 650-bp segment of
the promoter region of the rat insulin II gene truncated 30 bp upstream
of the initiation codon on exon 1 (19, 20) (generously provided by Dr.
Richard Flavell, Yale University) upstream of a 568-bp EcoRI-StyI
cDNA fragment of the human PTHrP(1–141) cDNA. This sequence
contains the entire pre-pro and coding region sequences of the
PTHrP(1–141) isoform but only 20 bp of 39 untranslated sequence (15).
Thus, the 39 AU-rich instability sequences normally present were de-
leted from this construct in an effort to enhance mRNA stability and
thereby enhance the level of expression of the transgene. Instead, at the
39 end of the transgene, human growth hormone sequences containing
transcription termination, polyadenylation, and splicing signals were
added as we have described previously (15). The resulting 3.4-kilobase
pair transgene was isolated, purified, and microinjected into the pro-
nuclei of (C57Bl6 3 SJL)F2 mouse ova in the Yale University Trans-
genic Mouse Core Facility to generate founder transgenic mice. Trans-
genic mice were identified by Southern blot analysis of BglI-digested
genomic DNA made from the tails of mice. The 568-bp hPTHrP cDNA
fragment was used as probe.
Using these procedures, 26 founder generation mice were obtained
from seven mothers. Of these 26 animals, seven were transgenic. Three
markedly dwarfed founders containing the highest copy number of the
transgene died shortly after birth, and two others were determined to
be mosaics in that they failed to transmit the transgene to their prog-
eny. Two true-breeding lines were generated from the two remaining
founders, animals 1799 and 1807. These were outbred onto a Sencar
background. The studies described herein were performed on animals
derived from the 1799 and 1807 lines. The two lines were maintained
separately, but because of their similar biochemical phenotypes, data
from the two lines have been pooled except where indicated below. All
of the studies described in this manuscript were performed on animals
between the ages of 5 and 12 weeks, unless specifically indicated. All
procedures were approved by the Yale University Animal Care and Use
Committee and the West Haven VA Medical Center Animal Studies
Committee.
RNA Analysis—Pancreas, heart, lung, liver, stomach, intestine,
spleen, kidney, testis, ovary, skin, pituitary, and brain from control and
transgenic animals as described under “Results” were harvested and
immediately frozen in liquid nitrogen. Total RNA was prepared using a
modification of the guanidinium thiocyanate-cesium chloride method
(21) or using the Trizol (Molecular Research Center) method. RNase
protection analysis was performed as described in detail previously (22)
using four different cRNA probes, which protected the following se-
quences: (i) a 349-bp band corresponding to an AvrII-PvuII fragment of
the mouse PTHrP gene, (ii) a 307-bp band corresponding to a PvuII-
SacI cDNA fragment of human PTHrP gene, (iii) a 220-bp band corre-
sponding to a Sau3A-Sau3A cDNA fragment of mouse cyclophilin gene,
and (iv) a 230-bp band corresponding to mouse insulin sequences pro-
tected by a PstI-AvaI mouse insulin genomic fragment (mouse insulin
genomic sequences courtesy of Dr. Shimon Efrat, Albert Einstein Col-
lege of Medicine, New York, NY).
Northern blotting of pituitary RNA was performed as described in
the legend to Fig. 11 using a mouse growth hormone cDNA probe,
generously provided by Dr. Daniel Linzer at the University of Chicago,
and a mouse proopiomelanocortin probe, generously provided by Dr.
Richard Mains at Johns Hopkins University.
Pancreatic Protein Extracts—Freshly dissected pancreata were im-
mediately frozen in liquid nitrogen, weighed, and extracts prepared by
the acid-urea method (23). Total protein concentrations of the extracts
were measured by the Bradford method (Bio-Rad). Insulin radioimmu-
noassays and PTHrP immunoradiometric assays were performed as
described below.
Plasma Analysis—Mice were bled retroorbitally into heparinized
capillary tubes and plasma separated by spinning in a microcentrifuge
for 10 min at 4 °C. Glucose was measured on whole blood using an
Accu-Chek III instrument (Boehringer Mannheim). Plasma calcium
was measured by atomic absorption spectrophotometry. Plasma insulin
levels were quantitated using two different RIAs as described in Fig. 5.
The first insulin RIA has been described previously (24) and was per-
formed in the laboratory of Dr. W. Zawalich. Briefly, this assay uses a
polyclonal guinea pig insulin antiserum (ICN Biomedicals, Costa Mesa,
CA) and a rat insulin standard (Eli Lilly, Indianapolis, IN). The detec-
tion limit of the assay is 195 pg/ml. The second insulin RIA was
performed using a kit purchased from Linco Research Inc., St. Louis,
MO, as described by the manufacturer. This assay has a detection limit
of 2.5 microunits/ml. PTHrP was measured using a rat modification (25)
of a human PTHrP(1–74) immunoradiometric assay, which has been
described previously in detail (26). The detection limit of this assay in
mouse plasma is 4 pM.
Plasma insulin-like growth factor 1 was measured by radioimmuno-
assay as described previously (27).
Immunohistochemistry and Quantitative Islet Histomorphometry.—
Pancreas was obtained from representative animals as described in
Results below, fixed overnight in 10% buffered formalin or Bouin’s
solution, and embedded in paraffin using standard techniques. Sections
were placed onto glass slides, deparaffinized with xylene, and either
stained with hematoxylin and eosin or incubated with affinity-purified
primary antisera recognizing human and mouse PTHrP (prepared in
our laboratory as described previously; Refs. 26 and 28) or with insulin,
glucagon, and somatostatin antisera purchased from Biogenix (San
Ramon, CA). Visualization of staining was accomplished using species-
appropriate avidin-biotin complex second antisera as described previ-
ously (28). Importantly, in all studies, sections of normal and transgenic
mouse pancreas were placed on the same slide to ensure identical
staining conditions. Sections from five normal and six transgenic mice
were stained with insulin and used for histomorphometric analysis.
Quantitative islet histomorphometry was performed using a Nikon
(Nikon Inc., New York, NY) Labophot microscope coupled to an Ost-
eotablet (Osteometrics, Atlanta, GA) planimeter and analyzed using the
Osteomeasure software package (Osteometrics) as we have reported
previously for use in quantitative bone histomorphometry (29).
Islet Perifusion—Pancreata were digested and islets isolated as de-
scribed in detail previously (30). Briefly, mice were anesthesized using
nembutal (50 mg/kg), the abdomen opened, and the pancreas removed
and incubated for 5–7 min in Collagenase P (5 mg/pancreas). The digest
was washed four times in Hank’s balanced salt solution, and individual
islets were manually harvested under a dissecting microscope and
placed onto a nylon membrane. Extreme care was taken to select islets
of equal size. The nylon membranes were then placed into perifusion
chambers and perifused at a rate of 1 ml/min with glucose added in the
concentrations indicated in the legend to Fig. 8. Fractions were col-
lected at 1-min intervals and assayed for insulin using the first insulin
RIA described above (24). Matched groups of 20–40 islets were used for
each perifusion assay. Four normal, four 1799 transgenic mice, and four
1807 transgenic mice were used for the experiments shown in Fig. 8.
RESULTS
RIP-PTHrP Mice Display a Dwarfed Phenotype—Each of the
seven founder RIP-PTHrP mice and every member of the F1
and subsequent generations of each of the two true-breeding
lines of RIP-PTHrP mice displayed a dwarfed penotype (Fig. 1).
The mice appeared normal in size at birth but were smaller
than their littermates within 1 week of life. The animals were
normally proportioned and appeared vigorous and healthy. The
size discrepancy was such that by 8 weeks of life, the RIP-
PTHrP mice were approximately 2⁄3 the weight (19 g versus 28
g for RIP-PTHrP versus normals) of their normal littermates.
The size discrepancy remained for the duration of their life
span. The pathophysiology responsible for the dwarfed pheno-
type is discussed below. For the current study, animals be-
tween the ages of 5 and 12 weeks of age were selected. This age
window was selected for study because by this age the animals
were old enough to permit easy access to blood samples for
multiple biochemical studies, but young enough that an ample
pool of animals could be maintained for the studies described
below. While animals outside the 5–12-week window have not
been studied to date in the detail described below, all informa-
tion available indicates that the hormonal abnormalities de-
scribed below are present throughout the life span of the
animals.
Overexpression of the RIP-PTHrP Transgene Is Targeted to
the Pancreatic Islet—In order to determine the level of expres-
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sion of the RIP-PTHrP transgene in the pancreas, RNase pro-
tection analysis of total RNA prepared from the pancreas of
normal and transgenic animals was performed (Fig. 2). As can
be seen in the figure, marked overexpression of the human
PTHrP was evident at the mRNA level in the pancreas of the
transgenic animals. As compared to the level of expression of
the endogenous murine PTHrP gene, the level of expression of
the transgene is roughly estimated to be 10–30-fold greater.
Human PTHrP mRNA was also expressed in other tissues,
including liver, stomach, heart, brain, kidney, and skin, but the
level of expression in tissues other than the pancreas was low,
comparable to the level of expression of the endogenous murine
PTHrP mRNA shown in Fig. 3, and considerably below the
level of expression observed in the pancreatic islet.
In order to confirm that the transgenic animals overexpress
the PTHrP at the peptide level, immunohistochemistry using
two region-specific anti-PTHrP antisera was performed. As can
be seen in Fig. 4, overexpression at the protein level is easily
apparent. PTHrP appears to be expressed in essentially all of
the cells of the islet using both PTHrP antisera. By rough
estimate, PTHrP expression would appear to be 3–10 times
higher in the RIP-PTHrP islet than in the normal islet.
Since the level of expression of the transgene was high, and
since the pancreatic islet is a secretory cell with direct access to
the circulation, it was important to determine whether sys-
temic oversecretion of PTHrP occurred. Serum calcium concen-
trations were normal in both lines of RIP-PTHrP mice (mean 6
S.E. 5 9.4 6 0.1 versus 9.3 6 0.2 mg/dl, normal versus RIP-
FIG. 2. RNase protection analysis of total RNA prepared from
pancreas from normal mice (N) and transgenic (T) RIP-PTHrP
mice. The panel on the left shows a 24-h exposure, and the panel on the
right shows the same gel exposed for 72 h. Note that the level of
pancreatic expression of the human transgene (hPTHrP) is dramatic at
the 24-h time point when the endogenous murine mRNA (mPTHrP) is
invisible, and that the endogenous mRNA only becomes visible after 72
h of exposure. A mouse cyclophilin probe serves as an internal control.
FIG. 3. Extra-islet expression of the RIP-PTHrP transgene. To-
tal RNA (100 mg) prepared from the tissues shown in the figure, both
from normal littermates (N) and transgenic animals (T), was analyzed
using RNase protection analysis. As can be seen, low levels of transgene
expression, as detected using the hPTHrP probe, were observed in the
stomach (Sto), intestine (Int), liver (Liv), heart (Hrt), lung (Lng), whole
brain (Brn), skin (Skn), and kidney (Kid). In general, mRNA expression
was comparable to endogenous mRNA as detected using the mPTHrP
probe. mCyclo indicates mouse cyclophilin. Gastric expression of the
endogenous PTHrP gene is higher than in any other organ. These
samples were obtained from animals with full stomachs; gastric disten-
tion has been reported to increase PTHrP expression (reviewed in
Ref. 13).
FIG. 4. Immunohistochemical staining for PTHrP. Immunohis-
tochemistry for amino-terminal PTHrP (left two panels) and mid-region
PTHrP (right two panels) in normal mouse pancreas (upper two panels)
and RIP-PTHrP transgenic mouse pancreas (middle two panels). Nor-
mal and transgenic pancreas sections were processed identically on
adjacent portions of the same slide as described under “Materials and
Methods.” The bottom panel shows staining of a RIP-PTHrP section
with the mid-region antibody following preincubation of the antibody
with 1026 M PTHrP(37–74). Identical loss of staining was obtained
when the amino-terminal antibody was preincubated with excess
PTHrP(1–36) (not shown). The results indicate that PTHrP, both ami-
no-terminal and mid-region epitopes, is present in the islets of the
RIP-PTHrP mouse in substantially greater than normal amounts. Al-
though colocalization studies using antibodies directed against insulin,
somatostatin, glucagon, and pancreatic polypeptide were not per-
formed, the pattern of staining is consistent with expression of the
transgene in b-cells and perhaps a-, d-, and PP cells as well.
FIG. 1. Appearance of the RIP-PTHrP mouse at 8 weeks of life
(left) as compared to an age-matched normal littermate (right).
Note that the RIP-PTHrP mouse is normally proportioned and healthy
appearing. The size discrepancy first becomes apparent at 2–3 weeks of
age and persists throughout life.
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PTHrP, respectively, n 5 10 animals in each group, p 5 N.S.),
and circulating PTHrP concentrations as determined using an
immunoradiometric assay for PTHrP(1–74) with a sensitivity
of 4 pM in the mouse (25, 26) were undetectable in both lines of
RIP-PTHrP mice. While appropriate samples of portal plasma
could not be obtained from these miniature aminals, it is worth
noting that an elevation in the portal concentration of PTHrP
has not been excluded.
RIP-PTHrP Mice Are Hypoglycemic and Hyperinsulinemic—
The results of plasma glucose and insulin determinations per-
formed on RIP-PTHrP and control mice between the ages of
5–12 weeks of age are shown in Fig. 5. As can be seen in the
three upper panels, blood glucose concentrations in normal
littermates are normal post-prandially in the non-fasting state
(i.e. at an 8–9 a.m. bleed after unrestricted access to food over
the preceding night), and after 8 h of fasting, and fall appro-
priately with progressively longer fasting. In contrast, the glu-
cose values are lower in the RIP-PTHrP mice at every time
point, both post-prandially and with progressively longer fast-
ing, and this difference was statistically different at every time
point.
As can be seen in the three lower panels of Fig. 5, plasma
insulin values were measured on the same samples from the
RIP-PTHrP mice and their normal littermates. Surprisingly, in
the non-fasting state, and after 8 h of fasting, plasma insulin
values were slightly (but not significantly) higher in the RIP-
PTHrP mice than in their normal littermates. Given the rela-
tive hypoglycemia in the RIP-PTHrP mice in the post-prandial
and 8-h fasted states, one would have expected the plasma
insulin values to have been lower in the RIP-PTHrP mice than
in controls at these two time points. Further, the plasma insu-
lin/glucose ratios were higher in the RIP-PTHrP mice than in
their normal littermates at both of these time points; in the
non-fasting state, the plasma insulin/glucose ratios (6 S.E.)
were 0.08 6 0.01 versus 0.05 6 0.01 (p 5 0.08) in the RIP-
PTHrP animals versus the normal littermates; corresponding
values after 8 h of fasting were 0.23 6 0.03 versus 0.14 6 0.02
(p 5 0.001).
After 24 h of fasting, insulin values were markedly higher in
the RIP-PTHrP animals than in their normal littermates, and
at this time point, the difference was highly significant in
statistical terms (p 5 0.002). Interestingly, the plasma insulin
values after 24 h of fasting were no different than the corre-
sponding values post-prandially (Fig. 5), indicating that
plasma insulin is not suppressible by fasting hypoglycemia in
the RIP-PTHrP mouse. Finally, in order to be certain that
inappropriate hyperinsulinemia was present, plasma insulin
concentrations were determined in two different laboratories
using two different plasma insulin immunoassays as described
under “Materials and Methods;” the values shown for the non-
fasting and 24-h time points were performed in one assay (the
Zawalich assay) and the 8-h fasting values in another (the
Linco assay).
Levels of steady-state insulin mRNA were determined using
RNase protection analysis of pancreatic total RNA. As shown in
Fig. 6a, steady state insulin mRNA levels were 2–3-fold higher
in the RIP-PTHrP mice as compared to their normal litter-
mates. This overexpression of insulin was confirmed at the
protein level by measuring insulin in pancreatic extracts by
radioimmunoassay. As can be seen in Fig. 6b, RIP-PTHrP mice
FIG. 5.Whole blood glucose (upper three panels) and plasma insulin (lower three panels) concentrations in non-fasting mice, after
an 8-h fast, and after a 24-h fast. NL indicates normal littermates, and TG indicates RIP-PTHrP mice. Note that the insulin RIA employed for
the non-fasting and the 24-h time points was the Zawalich insulin RIA (24), while that used for the 8 h time point was the Linco insulin RIA as
discussed under “Materials and Methods” and “Results.” The results indicate that glucose and insulin concentrations progressively and appro-
priately decline with fasting in the normal mice, whereas the RIP-PTHrP mice are hypoglycemic relative to their littermates at all time points
studied, are inappropriately hyperinsulinemic at all time points, and have non-suppressible plasma insulin concentrations even in the face of
marked hypoglycemia. The hyperinsulinemia is documented using two different insulin RIAs.
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contained more than twice as much insulin as those of their
normal littermates.
Immunohistochemistry using insulin, glucagon, and soma-
tostatin antisera is shown in Fig. 7. The distribution of insulin-,
glucagon-, and somatostatin-containing cells in the RIP-PTHrP
islet appears to be normal. No distributional or quantitative
differences were observed for any of these three islet peptides
between the RIP-PTHrP animals and their littermates.
Isolated RIP-PTHrP Islets Respond Normally to Glucose—
Hypoglycemia in the RIP-PTHrP mice could in theory arise
from a defect in glucose sensing, in insulin biosynthetic rates,
in the regulation of insulin release, or in a combination of the
above. In order to study these possibilities, isolated islets were
prepared from RIP-PTHrP mice and their littermates and peri-
fused with varying concentrations of glucose. As shown in
Fig. 8, neither perifusion with a low glucose concentration (2.75
mM or 50 mg/dl) nor perifusion using a high glucose concentra-
tion (20 mM or 360 mg/dl) revealed differences in insulin secre-
tion between RIP-PTHrP and normal islets. Indistinguishable
results also were observed when normal and RIP-PTHrP islets
were perifused using 0 mM and 10 mM glucose perifusates (data
not shown). These results suggested that the hyperinsulinemia
and hypoglycemia observed in vivo and the elevated pancreatic
insulin peptide and mRNA values may not result from abnor-
malities in individual islets or islet cells, but may reflect an
increase in islet mass.
Islet Number and Islet Cell Mass Are Increased in the RIP-
PTHrP Mouse—Initial unblinded histologic examination of the
pancreata from RIP-PTHrP mice suggested that these animals
had more than a normal allotment of pancreatic islets (Fig. 9).
In order to determine whether this was in fact the case, a
blinded systematic quantitative histomorphometric analysis of
the pancreata from normal littermates and RIP-PTHrP trans-
genic animals was performed. Five control animals and five
age- and sex-matched transgenic animals were sacrificed, the
pancreata completely removed, and sections from each pan-
creas (representing the pancreatic head, body and tail) ob-
tained. Each section was stained for insulin so that all islets of
all sizes were included. These sections were quantitated by a
blinded histomorphometrist with respect to islet number per
unit of exocrine pancreatic area and total islet volume per unit
of exocrine pancreas volume. The results are shown in Fig. 10.
Both islet number and the islet volume were found to be be-
tween 2- and 3-fold increased in the RIP-PTHrP animals as
compared to their littermates. Extrapolating from these data,
the mean volume of individual islets can be predicted to be
normal or near normal in the RIP-PTHrP animals.
Dwarfisim in the RIP-PTHrP Mouse Results from Growth
Hormone Deficiency—The dwarfed phenotype was unexpected
since hyperinsulinemia would be predicted, if anything, to re-
sult in hypersomatism. The results of pituitary growth hor-
mone mRNA levels and of circulating IGF-1 are shown in Fig.
11. Messenger RNA for growth hormone is dramatically re-
duced in the pituitary of both strains of RIP-PTHrP mouse,
while levels of proopiomelanocortin mRNA, the precursor for
ACTH, are comparable in normal and transgenic animals. The
reduction in growth hormone mRNA is accompanied by an
equally striking reduction in plasma IGF-1 concentrations, also
observed in both strains of RIP-PTHrP mouse.
DISCUSSION
These studies demonstrate that PTHrP overexpression in
the pancreatic b cells of transgenic mice leads to a syndrome of
hypoglycemia resulting from hyperinsulinemia. Taken to-
gether with the observations that PTHrP is normally produced
in pancreatic b cells (7, 8, 18), and is capable in doses that are
FIG. 6. Pancreatic insulin mRNA and insulin content. Panel A
shows steady-state insulin mRNA levels as assessed using RNase pro-
tection analysis of total pancreatic RNA from normal littermates (N)
and from RIP-PTHrP transgenic (T) animals from lines 1799 and 1807.
The probes used were a mouse insulin and a mouse cyclophilin cRNA as
indicated in the Fig. and described in detail under “Materials and
Methods.” Panel B shows the insulin content of normal and transgenic
pancreas acid-urea extracts prepared and assayed as described under
“Materials and Methods.” Note that both pancreatic insulin mRNA and
insulin protein are 2–3-fold higher in the RIP-PTHrP pancreata than in
those of their normal littermates.
FIG. 7. Immunohistochemical staining for insulin, glucagon
and somatostatin in paraffin sections of RIP-PTHrP pancreas.
Staining for insulin (upper left), glucagon (lower left), and somatostatin
(upper right) appear normal in the RIP-PTHrP islet, and are indistin-
guishable from staining patterns and intensities for the same three
peptides in sections of pancreas of normal littermates (data not shown).
The bottom right panel is a section for which the primary antibody was
omitted, demonstrating the specificity of the staining.
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well within the physiologic range (10212 to 1028 M) of eliciting
cytosolic calcium responses in a cultured b cell line (18), these
findings suggest that PTHrP may play a normal paracrine,
autocrine or perhaps “intracrine” (11, 12) physiologic role
within the pancreatic islet, and that this role directly or indi-
rectly may involve the regulation, biosynthesis or secretion of
insulin.
A primary question regards the mechanisms responsible for
hyperinsulinemia in the RIP-PTHrP mouse. It is in theory
possible that hyperinsulinemia and hypoglycemia result from
islet-specific effects of the promoter or to random insertional
events relating to the location of the transgene in the murine
genome. The RIP promoter used in these studies has been used
extensively in the creation of other transgenic mouse models.
In two models of RIP promoter-targeted transgenic mice, one
involving yeast hexokinase (31) and the other involving vaso-
active intestinal polypeptide (32), hypoglycemia and hyperin-
sulinemia did occur. In these cases, there were sound physio-
logic reasons for the occurrence of hypoglycemia. The other
RIP-transgenic models, e.g. the RIP-Tag mouse (19, 20), the
RIP-Gsa mouse (33), the RIP-TNF-b mouse (34), and the RIP-
MHC-II mouse (35), do not develop hypoglycemia, but more
typically develop glucose intolerance or frank diabetes. Since
most RIP transgenic models do not develop hypoglycemia, and
since the hypoglycemia and hyperinsulinemia were observed in
two independent lines of RIP-PTHrP mice, it is unlikely that
random insertional mutagenesis or islet-specific effects of the
RIP promoter can explain the findings. Rather, the results
would appear to be a specific consequence of PTHrP overex-
pression in the pancreatic islet.
Hyperinsulinemia was accompanied by increases in pancre-
atic insulin peptide and mRNA content. No qualitative or quan-
titative abnormalities in glucagon or somatostatin immunohis-
tochemistry could be detected.
Hyperinsulinemia could result in the RIP-PTHrP mouse
from abnormalities in individual islet cells and/or within indi-
vidual islets. These defects could include abnormalities in b cell
glucose sensing, inappropriate rates of insulin biosynthesis, a
failure of the normal regulation of insulin secretory mecha-
nisms within the b cell or a combination of the above. In order
to test these possibilities, perifusion experiments were per-
formed using islets isolated from RIP-PTHrP transgenic ani-
mals and their normal littermates. When compared in this
way, individual transgenic islets apperared to sense glucose
and secrete insulin appropriately. Insulin secretion was normal
in response to 0, 2.75, 10, and 20 mM glucose perifusion. These
findings support the interpretation that there are no intrinsic
abnormalities in the RIP-PTHrP islet or in individual RIP-
PTHrP b cells, but rather that the hyperinsulinemia and hy-
poglycemia might result instead from the observed increase in
islet cell mass.
Two observations made during the preliminary characteriza-
tion of the animals suggested that an increase in islet cell mass
was present in the RIP-PTHrP mice. First, in the course of islet
FIG. 8. Perifusion of isolated islets derived from RIP-PTHrP
mice and their normal littermates. Perifusion was performed as
described under “Materials and Methods” on isolated islets with either
low glucose (G2.75 5 2.75 mM or 50 mg/dl glucose) or high glucose (G20
5 20 mM or 360 mg/dl glucose) for the times indicated. As indicated in
the key on the right, large closed circles represent the results of four
perifusions of islet from four normal animals, small closed circles the
results of four perifusions of islets from four RIP-PTHrP mice of the
1799 line, and squares, four perifusions of the islets from four RIP-
PTHrP mice of the 1807 line. The diamonds are the mean of all the
transgenic data, and thus represent the results of eight perifusions of
islets isolated from eight mice.
FIG. 9. Hematoxylin and eosin
staining of representative sections of
pancreas from normal mice (panel A)
and RIP-PTHrP mice (panel B). Note
that the RIP-PTHrP appear to have more
than the normal number of islets, and
that the islets appear to display a normal
size distribution.
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isolation for the perifusion studies, islets appeared to be of
normal size but were more abundant and therefore easier to
harvest from the RIP-PTHrP mice than from those of their
normal littermates. Second, in initial histologic study of the
pancreata from the RIP-PTHrP mice, it appeared that islets
were more abundant than in their littermates. In order to
examine this posibility in a formal manner, multiple histologic
sections were prepared from pancreata from multiple RIP-
PTHrP and control animals and these were subjected in a
blinded fashion to quantitative islet histomorphometry. The
quantitative histomorphometric findings confirmed our initial
subjective impression; the RIP-PTHrP mice had approximately
twice as many pancreatic islets per unit area of exocrine pan-
creas as did their littermates; and the aggregate islet area or
volume in the RIP-PTHrP mouse was approximately 2-fold
higher in the RIP-PTHrP mice than their littermates. By ex-
trapolation, the average islet size would be normal in the
RIP-PTHrP mouse.
These observations raise two questions. The first question is,
“Given that the RIP-PTHrP mice are smaller than their litter-
mates, do the islet histomorphometric findings represent an
appropriately normal islet mass in otherwise miniature mice or
should the islet mass be reduced in miniature mice?” This
question is difficult to answer unequivocally from available
information, but several points bear mention. First, in the Snell
and the Ames dwarf growth hormone-deficient mouse models,
islet mass is reduced in concert with body size (36). Second, the
hypoglycemia observed in the RIP-PTHrP mouse per se would
be expected to reduce islet proliferation rates and thereby
reduce, not increase, islet mass. Third, in preliminary studies,
RIP-PTHrP mice of all ages and sizes are hypoglycemic and
hyperinsulinemic.
2
Thus, it is difficult to avoid the conclusion
that islet mass is inappropriately and absolutely increased in
the RIP-PTHrP mouse.
The second question is, “Is a 2-fold increase in islet mass
sufficient to cause hyperinsulinemia and hypoglycemia in oth-
erwise normal mice?” Again, this question is difficult to answer
from available data. Islet transplant experiments in which
pancreatic islets have been harvested from syngeneic animals
and transplanted into normal rats and mice in order to produce
models of hyperinsulinemia and hypoglycemia have generally
employed more than double the normal allotment of islets, but
the viability of the transplanted islets is difficult to know in
such studies and could conceivably be such that a 2-fold in-
crease in islet mass was achieved. In patients with insulino-
mas, islet mass is probably not more than double, but insuli-
nomas have intrinsic glucose sensing and insulin secretory
abnormalities that account for insulin oversecretion (37). Our
bias would be that a 2-fold increase in islet mass should be
insufficient for the induction of hypoglycemia, and that despite
the perifusion study results, suggesting that glucose sensing
and the regulation of insulin secretion are normal, the RIP-
PTHrP islets or individual b cells have intrinsic glucose-sens-
ing or insulin regulatory abnormalities that lead to inappropri-
ate insulin secretion, and that were not detected using our
perifusion method. In preliminary studies, we have found that
administration of synthetic PTHrP(1–36) or PTHrP(1–74) by
perifusion to normal islets does not influence insulin secretion.
Clarification of these possiblities must await further study.
PTHrP is produced in a broad range of normal tissues. It has
2 R. C. Vasavada and A. F. Stewart, unpublished observations.
FIG. 10. Quantitative islet histomorphometry of normal (NL)
and RIP-PTHrP transgenic (TG) pancreas. The upper panel shows
the volume of pancreatic islets as a function of arbitrary total pancre-
atic volume units. The lower panel displays the number of islets per
square millimeter of total pancreatic area. Although not directly meas-
ured, it can be extrapolated from these findings that the mean volume
or area of individual islets in normal and transgenic animals is
comparable.
FIG. 11. Panel A, expression of murine growth hormone (mGH) and
murine proopiomelanocortin (mPOMC) mRNA in the pituitary of nor-
mal littermates (N) and transgenic animals (T). Five mg of pituitary
total RNA prepared from pituitaries pooled from five animals was
loaded in each lane. This blot was prepared from animals of the 1807
line, but indistinguishable results were found in the 1799 line as well.
Panel B, circulating insulin-like growth factor 1 concentrations in nor-
mal and transgenic animals. See text for details.
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been shown to have important effects on growth, development,
and differentiation in many tissues (reviewed in Refs. 1–6 and
13), including the epidermal keratinocyte, the osteoblast, the
chondrocyte, the fibroblast, the mammary myoepithelial cell,
the renal proximal tubular cell, embryonic teratoma cells, and
others. No studies have been reported examining the possible
role of PTHrP as a mitogen, or developmental or differentiating
factor in the pancreatic islet. However, Drucker and collabora-
tors have shown that butyrate, which induces differentiation in
cultured pancreatic b cell lines, co-induced the expression of
PTHrP in these cells (38). The increased pancreatic islet cell
mass in the RIP-PTHrP mouse is consistent with a role for
PTHrP as a factor that regulates islet cell mass. It is worth
noting that disruption of the PTHrP gene has been accom-
plished in a mouse model by Karaplis and colleagues (16). The
“PTHrP knockout” mouse has severe skeletal abnormalities.
Unfortunately, however, these animals die immediately follow-
ing parturition, prior to the complete development of pancre-
atic islets. This early lethality together with the absence of
information regarding insulin and glucose homeostasis in these
animals means that the consequences of PTHrP gene disrup-
tion on islet formation and function remain unknown in these
animals. Further studies will be required to determine whether
PTHrP is in fact a growth regulatory peptide in the islet, and if
so, whether these effects occur primarily developmentally in
utero or continue into adult life. The potential role for PTHrP
as an islet growth factor is significant given the failure of the b
cell in Type II diabetes mellitus, given the long term failure of
islet cell transplantation despite the development of potent and
effective immunosuppressive agents, and given the current
paucity of well defined islet growth factors.
PTHrP is a prohormone that is posttranslationally endopro-
teolytically cleaved to yield a family of mature secretory pep-
tides (3–5). These include an amino-terminal secretory form,
which binds to and activates the recently cloned parathyroid
hormone receptor (10), as well as several other mid-region, and
carboxyl-terminal secretory forms of the peptide. In the current
experiment, since the full-length PTHrP(1–141) cDNA was
used to construct the transgene, these experiments do not
provide information regarding which of the several secretory
forms is (or are) responsible for the hyperinsulinemia and islet
hyperplasia observed.
The dwarfed phenotype was particularly surprising given
the presence of hyperinsulinemia. In preliminary studies, RIP-
PTHrP mice are dwarfed as compared to their littermates
throughout their normal lifespan.2 The animals are healthy
and vigorous-appearing throughout life, are not hypercalcemic,
and have no organ or tissue abnormalities at post-mortem
examination. Furthermore, none of the several other RIP
transgenic models described to date have displayed dwarfism
as a part of the phenotype (19, 20, 30–34). Thus, it is likely that
dwarfism occurs not as an artifactual result of the transgene
but as a specific consequence of PTHrP overexpression. Plasma
IGF-1 concentrations were strikingly reduced, and these in
turn would appear to have resulted from a similarly striking
reduction in growth hormone. It seems likely that dwarfism
results from low level “leaky” expression of the transgene in the
hypothalamus or pituitary (low levels of transgene expression
were observed in tissues outside the islet in the RIP-PTHrP
mouse as they have in other RIP- transgenic mice; see Refs. 19,
20, and 31–35). Northern analysis of pituitary RNA failed to
detect PTHrP mRNA in either normal or transgenic pituitary
(not shown). PTHrP is slightly overexpressed in RNA prepared
from whole brain of the transgenic animals (Fig. 3), but it is not
yet clear whether there is overexpression of PTHrP in the
hypothalamus. If overexpression were to occur in the hypothal-
amus, it would suggest that PTHrP may inhibit growth hor-
mone or GHRH production or secretion, and would imply that
PTHrP might play a normal physiologic role in their regula-
tion. Studies designed to clarify these issues are under way. In
the context of the current study, however, growth hormone
deficiency or consequent insulin-like growth factor I deficiency
would not be expected to lead to hyperinsulinemia, hypoglyce-
mia and islet hyperplasia. Thus, the growth abnormality is
almost certainly independent from the glucose homeostatic
abnormalities observed.
In summary, these studies indicate that PTHrP may play a
normal physiologic role as a regulator of islet cell mass, and
through this mechanism or perhaps others, may play a normal
role in the physiologic regulation of insulin secretion. Further
studies are required to define the cellular mechanisms under-
lying the islet mass-regulating properties of PTHrP, to define
the developmental pathobiology of the pancreas and glucose
homeostasis in the RIP-PTHrP mouse, and to fully define the
mechanisms responsible for dwarfing.
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